Raltegravir
Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.
Dosing in kidney impairment
Use in Patients with Renal Impairment No dosage adjustment of raltegravir is necessary in patients with any degree of renal impairment [see Clinical Pharmacology ] . The extent to which raltegravir may be dialyzable is unknown; therefore, dosing before a dialysis session should be avoided.
Dosing in liver impairment
Use in Patients with Hepatic Impairment No dosage adjustment of raltegravir is necessary for patients with mild to moderate (Child-Pugh A and B) hepatic impairment. No hepatic impairment study has been conducted with ISENTRESS HD and therefore administration in subjects with hepatic impairment is not recommended. The effect of severe hepatic impairment on the pharmacokinetics of raltegravir has not been studied [see Clinical Pharmacology ] .